Description: Neuvasq Biotechnologies is a privately held research company focusing on the discovery and development of pioneering therapies to safeguard or rebuild central
NeuVasQ is developing pharmaceuticals to restore blood-brain barrier function in acute neurological disorders such as stroke, epilepsy and neurodegenerative diseases like Alzheimer’s.
NeuVasQ is based on new insights into the molecular mechanisms maintaining the integrity of the blood-brain barrier (BBB). The BBB regulates the exchange between the vascular system and central nervous system (CNS). Increased BBB permeability, due to age or injury, is involved in many neurological conditions through the leakage of harmful blood substances into the CNS. BBB dysfunction is a factor in many neurodegenerative disorders, such as Alzheimer’s, as well as multiple acute neurological conditions like
By precisely targeting the pathways responsible for BBB integrity, NeuVasQ has been able to restore lost functionality to the neurovasculature. This unique and targeted approach has the potential to safely improve patient lives in a wide range of neurological disorders.